Targeting m6A alterations in cancer has therapeutic potential since METTL3 inhibitors have been demonstrated to stop leukemia cell proliferation and improve their sensitivity to chemotherapeutic therapies (Zhang et al., 2020[165]; Zhang et al., 2022[166]). This evidence concerns the gene METTL3 and cancer.